Antares Pharma

Antares Pharma is a revenue-generating product-focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA-approved products. Its products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. It focuses on self-injection pharmaceutical products and technologies and topical gel-based products. Its subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto-injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Antares Pharma (NASDAQ: ATRS) shares are trading higher on Monday after the company announced a deal with Lunatus Global to distribute and promote XYOSTED in Saudi Arabia.

Why Antares Pharma's Stock Is Trading Higher Today

EWING, N.J., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with Lunatus Global Medical Supplies (“Lunatus”) to distribute and promote the sale of  XYOSTED® in Saudi Arabia and the United Arab Emirates (“UAE”). 

Antares Pharma and Lunatus Enter Into an Exclusive Distribution Agreement for XYOSTED® in Saudi Arabia and the United Arab Emirates

EWING, N.J., July  21, 2020  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the Company’s multi-dose pen platform launched in Europe. Antares development partner Teva, launched Teriparatide Injection (“teriparatide”), the generic version of Eli Lilly’s brand product Forsteo®  featuring the Antares multi-dose pen platform in Austria, Croatia, Hungary, The Netherlands, Portugal, Sweden, Switzerland and The United Kingdom and is expected to launch in other European countries later this year.

First Commercial Product Using Antares Pharma’s  Multi-Dose Pen Platform Launches in Europe

EWING, N.J., July  20, 2020  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to the position of Senior Vice President of Commercial.  Mr. Shea will be responsible for leading all commercial activities including sales, sales operations, marketing, trade and market access for the Company and will report to Robert F. Apple, Antares Pharma’s President and Chief Executive Officer.   In his role, Mr. Shea’s primary responsibilities will be to accelerate the positive growth trajectory of the Company’s flagship product XYOSTED® as well as strategic assessment of future potential product opportunities for the commercial organization.  He will be replacing Edward Kessig, Senior Vice President of Commercial, who has recently announced his retirement.

Antares Pharma Appoints Patrick Shea Senior Vice President of Commercial

Antares Continues To Quietly Grow Revenue

EWING, N.J., June  11, 2020  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 9:40 a.m. Eastern Time.

Antares Pharma to Present at the Raymond James Human Health Innovation Conference

Why is a fast-growing company making one of the best testosterone replacement therapies on the market so underappreciated by investors?

Why Is This Fast-Growing Biotech So Undervalued?

Apple

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2020 Results - Earnings Call Transcript

First-quarter financial results failed to spark investors' animal spirits.

Why Antares Pharma Is Crashing 12.3% Today

Antares Pharma: An Undervalued Stock To Buy During The COVID-19 Crisis

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q4 2019 Results - Earnings Call Transcript

Products from the pharmaceutical technology company continued to pick up momentum in the fourth quarter.

How Antares Pharma Beat Expectations in Q4

Antares Pharma: Reasonable Expectations For 2020

Antares Pharma: XYOSTED's Prescription Growth Is Running On All Cylinders

The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance

Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million

Investors are locking in gains in this fast-growing drugmaker.

Why Antares Pharma's Sliding 10% Today

EWING, N.J., Dec.  10, 2019  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. Tykot is a seasoned corporate and business development executive with a proven record of success in both small and large pharmaceutical companies.

Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development

EWING, N.J., Dec.  06, 2019  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored with a 2019 MarCom Platinum Award.  The award is the highest level achievable in the international marketing competition.

Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award

Antares' Xyosted Is One Of The Best Testosterone Replacement Therapies Available

Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction

REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

EWING, N.J., Oct.  31, 2019  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “Company”) today announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals (“Ferring”) in connection with the previously disclosed sale of Antares’ worldwide rights, including certain fixed assets, for the ZOMAJET™ needle-free auto injector device to Ferring. Antares had been the worldwide supplier of ZOMAJET™ devices to Ferring and JCR Pharmaceutical Company Ltd.

Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System

EWING, N.J., Oct.  24, 2019  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from two poster presentations will be presented on Saturday October 26, 2019 at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA).   

Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

EWING, N.J., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 12:00 p.m. Eastern Time.

Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Every 1% of market share captured by XYOSTED in the testosterone replacement therapy market would grant ATRS $8.5 million in annual sales.

News for Antares Pharma Stock (ATRS)